TBH Global Asset Management LLC Sells 5,886 Shares of Pfizer Inc. (NYSE:PFE)

TBH Global Asset Management LLC decreased its position in Pfizer Inc. (NYSE:PFE) by 18.5% in the 4th quarter, HoldingsChannel.com reports. The fund owned 25,967 shares of the biopharmaceutical company’s stock after selling 5,886 shares during the quarter. TBH Global Asset Management LLC’s holdings in Pfizer were worth $748,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the company. Team Hewins LLC bought a new position in Pfizer in the 4th quarter valued at $1,093,000. TCW Group Inc. increased its holdings in Pfizer by 82.7% during the fourth quarter. TCW Group Inc. now owns 205,376 shares of the biopharmaceutical company’s stock worth $5,913,000 after buying an additional 92,970 shares during the last quarter. SageView Advisory Group LLC raised its position in Pfizer by 2.2% in the fourth quarter. SageView Advisory Group LLC now owns 45,186 shares of the biopharmaceutical company’s stock worth $1,221,000 after acquiring an additional 973 shares during the period. Commerce Bank boosted its stake in Pfizer by 4.8% in the fourth quarter. Commerce Bank now owns 2,503,870 shares of the biopharmaceutical company’s stock valued at $72,086,000 after acquiring an additional 114,342 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. grew its position in shares of Pfizer by 9.4% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 1,589,652 shares of the biopharmaceutical company’s stock valued at $45,766,000 after acquiring an additional 136,467 shares during the period. 68.36% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently commented on PFE. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Monday, April 15th. Morgan Stanley lifted their price objective on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, May 2nd. Guggenheim initiated coverage on shares of Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective on the stock. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 price objective (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Ten research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $35.86.

Pfizer Price Performance

Shares of PFE traded up $0.19 during trading hours on Friday, reaching $28.88. 22,589,127 shares of the company’s stock traded hands, compared to its average volume of 44,974,800. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $40.37. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. The stock has a market cap of $163.65 billion, a PE ratio of -481.25, a price-to-earnings-growth ratio of 1.13 and a beta of 0.63. The firm’s 50 day simple moving average is $27.27 and its 200-day simple moving average is $27.96.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. The business had revenue of $14.88 billion during the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business’s quarterly revenue was down 19.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.23 EPS. Equities analysts expect that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be paid a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 5.82%. The ex-dividend date is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is currently -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.